NO20081974L - Antistoff-drug-konjugater og fremgangsmater for anvendelse av disse - Google Patents

Antistoff-drug-konjugater og fremgangsmater for anvendelse av disse

Info

Publication number: NO20081974L
Authority: NO; Norway
Prior art keywords: antibody; drug conjugates; methods; drug; conjugates
Prior art date: 2005-09-26

Application number

NO20081974A

Other languages

English (en)

Norwegian (no)

Inventor

Josephine M Cardarelli

Sanjeev Gangwar

Haichun Huang

Chin Pan

Sharon Elaine Boyd

Liang Chen

Vincent Guerlavais

Kilian Horgan

Bilal Sufi

David John King

Original Assignee

Medarex Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-26

Filing date

2008-04-24

Publication date

2008-06-09

2008-04-24 Application filed by Medarex Llc filed Critical Medarex Llc

2008-06-09 Publication of NO20081974L publication Critical patent/NO20081974L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6805—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a vinca alkaloid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Nanotechnology (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Reproductive Health (AREA)
Physics & Mathematics (AREA)
Composite Materials (AREA)
Condensed Matter Physics & Semiconductors (AREA)
General Physics & Mathematics (AREA)
Materials Engineering (AREA)
Crystallography & Structural Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Mycology (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Biotechnology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20081974A 2005-09-26 2008-04-24 Antistoff-drug-konjugater og fremgangsmater for anvendelse av disse NO20081974L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US72049905P	2005-09-26	2005-09-26
PCT/US2006/037793 WO2007038658A2 (fr)	2005-09-26	2006-09-26	Conjugues anticorps-medicament et leurs methodes d'utilisation

Publications (1)

Publication Number	Publication Date
NO20081974L true NO20081974L (no)	2008-06-09

Family

ID=37900452

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20081974A NO20081974L (no)	2005-09-26	2008-04-24	Antistoff-drug-konjugater og fremgangsmater for anvendelse av disse

Country Status (15)

Country	Link
US (1)	US20080279868A1 (fr)
EP (2)	EP2354163A3 (fr)
JP (1)	JP5290756B2 (fr)
KR (1)	KR101377373B1 (fr)
CN (1)	CN101312748A (fr)
AU (1)	AU2006294554B2 (fr)
BR (1)	BRPI0617546A2 (fr)
CA (1)	CA2623652C (fr)
EA (1)	EA016577B1 (fr)
ES (1)	ES2416136T3 (fr)
IL (1)	IL190187A (fr)
NO (1)	NO20081974L (fr)
NZ (1)	NZ566982A (fr)
WO (1)	WO2007038658A2 (fr)
ZA (1)	ZA200803153B (fr)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2163256B1 (fr)	2001-05-11	2015-09-02	Ludwig Institute for Cancer Research Ltd.	Protéines à liaison spécifique et leurs utilisations
US20100056762A1 (en)	2001-05-11	2010-03-04	Old Lloyd J	Specific binding proteins and uses thereof
US20050215472A1 (en)	2001-10-23	2005-09-29	Psma Development Company, Llc	PSMA formulations and uses thereof
EP2363404B8 (fr)	2001-10-23	2016-12-07	PSMA Development Company L.L.C.	Anticorps contre le PSMA
US8877901B2 (en)	2002-12-13	2014-11-04	Immunomedics, Inc.	Camptothecin-binding moiety conjugates
CN101267841B (zh)	2005-08-24	2012-10-10	免疫原公司	制备美登木素生物碱抗体缀合物的方法
EP1934261B1 (fr)	2005-09-26	2014-10-29	Medarex, L.L.C.	Anticorps monoclonaux humains diriges contre cd70
JP5525729B2 (ja)	2005-11-28	2014-06-18	ゲンマブエー／エス	組換え一価抗体およびその作製方法
SG170080A1 (en)	2005-12-08	2011-04-29	Medarex Inc	Human monoclonal antibodies to o8e
SI1957539T1 (sl)	2005-12-08	2013-05-31	Medarex, Inc.	Humana monoklonska protitelesa proti protein tirozin kinazi 7 (PTK7) in njihova uporaba
US20100150950A1 (en)	2006-12-14	2010-06-17	Medarex, Inc.	Human antibodies that bind cd70 and uses thereof
TWI412367B (zh)	2006-12-28	2013-10-21	Medarex Llc	化學鏈接劑與可裂解基質以及其之綴合物
JP5276017B2 (ja)	2007-01-25	2013-08-28	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	Ｅｇｆｒ変異体仲介性疾患の治療における抗ｅｇｆｒ抗体の使用
US8664407B2 (en)	2007-02-21	2014-03-04	Medarex, LLC	Chemical linkers with single amino acids and conjugates thereof
US9023356B2 (en)	2007-03-15	2015-05-05	Ludwig Institute For Cancer Research Ltd	Treatment method using EGFR antibodies and SRC inhibitors and related formulations
WO2008145139A1 (fr) *	2007-05-31	2008-12-04	Genmab A/S	Protéines de fusion ou liéee à demi-vie étendue
US9901567B2 (en)	2007-08-01	2018-02-27	Syntarga B.V.	Substituted CC-1065 analogs and their conjugates
US9283276B2 (en)	2007-08-14	2016-03-15	Ludwig Institute For Cancer Research Ltd.	Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
EP2185188B1 (fr)	2007-08-22	2014-08-06	Medarex, L.L.C.	Attachement spécifique d'un site de médicaments ou autres agents à des anticorps synthétisés par génie génétique avec des extensions c-terminales
AU2008308956B2 (en)	2007-10-01	2013-03-14	Bristol-Myers Squibb Company	Human antibodies that bind mesothelin, and uses thereof
TW200938224A (en) *	2007-11-30	2009-09-16	Medarex Inc	Anti-B7H4 monoclonal antibody-drug conjugate and methods of use
KR20100101124A (ko) *	2007-11-30	2010-09-16	브리스톨-마이어스 스큅 컴퍼니	단백질 티로신 키나제 ７ (ｐｔｋ７)에 대한 모노클로날 항체 파트너 분자 컨쥬게이트
JP2011505371A (ja) *	2007-11-30	2011-02-24	ブリストル−マイヤーズスクイブカンパニー	抗−ｒｇ−１抗体の複合体
US20090148535A1 (en) *	2007-12-06	2009-06-11	Minerva Biotechnologies Corporation	Method for treating cancer using interference rna
WO2009127046A1 (fr) *	2008-04-14	2009-10-22	Proscan Rx Pharma Inc.	Anticorps d’antigene membranaire specifique de la prostate et fragments de liaison a l’antigene
AR072999A1 (es)	2008-08-11	2010-10-06	Medarex Inc	Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010027513A2 (fr)	2008-09-08	2010-03-11	Psma Development Company, Llc	Procédés pour tuer des cellules cancéreuses exprimant psma et résistantes au taxane
NO2344478T3 (fr) *	2008-11-03	2018-02-24
US20110287036A1 (en) *	2008-11-17	2011-11-24	Riken	Novel cancer targeting therapy using complex of subtance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound
EP3939617B1 (fr)	2009-02-13	2024-11-13	Immunomedics, Inc.	Composés intermédiaires pour la préparation de conjugués comportant une liaison intracellulaire clivable
LT2403878T (lt)	2009-03-05	2017-10-10	E. R. Squibb & Sons, L.L.C.	Pilnai žmogaus specifiniai antikūnai, skirti cadm1
SI2437790T1 (sl)	2009-06-03	2019-07-31	Immunogen, Inc.	Konjugacijske metode
US8394922B2 (en) *	2009-08-03	2013-03-12	Medarex, Inc.	Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
EP2478013B1 (fr)	2009-09-16	2018-10-24	F.Hoffmann-La Roche Ag	Complexes protéiques contenant une super-hélice et/ou une attache et leurs utilisations
TW201138821A (en)	2010-03-26	2011-11-16	Roche Glycart Ag	Bispecific antibodies
DK2560645T3 (en)	2010-04-21	2016-10-10	Syntarga Bv	Conjugates of CC-1065 analogs and bifunctional linking groups
US8956859B1 (en)	2010-08-13	2015-02-17	Aviex Technologies Llc	Compositions and methods for determining successful immunization by one or more vaccines
CA2930801C (fr)	2010-11-05	2019-05-28	Rinat Neuroscience Corporation	Conjugues de polypeptides obtenus par genie biologique, et procede de fabrication correspondants au moyen de transglutaminase
SG191153A1 (en)	2010-12-23	2013-07-31	Hoffmann La Roche	Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2668210B1 (fr)	2011-01-26	2020-06-17	Celldex Therapeutics, Inc.	Anticorps anti-kit et leurs utilisations
PT2691155T (pt)	2011-03-29	2019-02-19	Immunogen Inc	Preparação de conjugados de anticorpo de maitansinoide por processo de uma etapa
US8852599B2 (en) *	2011-05-26	2014-10-07	Bristol-Myers Squibb Company	Immunoconjugates, compositions for making them, and methods of making and use
US11147852B2 (en)	2011-12-23	2021-10-19	Pfizer Inc.	Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
CA2861124A1 (fr)	2012-02-10	2013-08-15	Genentech, Inc.	Anticorps et autres heteromultimeres monocatenaires
KR101660146B1 (ko)	2012-02-13	2016-09-26	브리스톨-마이어스 스큅 컴퍼니	에네디인 화합물, 그의 접합체, 및 그에 대한 용도 및 방법
US9504756B2 (en)	2012-05-15	2016-11-29	Seattle Genetics, Inc.	Self-stabilizing linker conjugates
WO2013173337A2 (fr)	2012-05-15	2013-11-21	Seattle Genetics, Inc.	Conjugués de lieurs à auto-stabilisation
EP2850059A4 (fr) *	2012-05-15	2016-06-29	Concortis Biosystems Corp	Conjugués de médicament, procédés de conjugaison et utilisation de ceux-ci
CN110256567B (zh)	2012-06-27	2023-04-25	弗·哈夫曼-拉罗切有限公司	用于选择并产生含有至少两种不同结合实体的定制靶向实体的方法及其用途
RU2015100656A (ru)	2012-06-27	2016-08-20	Ф. Хоффманн-Ля Рош Аг	Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
BR112014029888A2 (pt)	2012-06-27	2020-05-12	Hoffmann La Roche	Métodos de produção de um anticorpo, de determinação de uma combinação de sítios de ligação e de tratamento de um indivíduo com câncer, formulação farmacêutica, anticorpo e uso de um anticorpo
AR091649A1 (es)	2012-07-02	2015-02-18	Bristol Myers Squibb Co	Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN102742580B (zh) *	2012-07-16	2014-04-02	广东省农业科学院植物保护研究所	醌霉素a制剂及其制备方法与应用
DK2877493T3 (en)	2012-07-25	2018-06-14	Celldex Therapeutics Inc	ANTI-KIT ANTIBODIES AND APPLICATIONS THEREOF
HK1213288A1 (zh)	2012-10-04	2016-06-30	Immunogen, Inc.	使用pvdf膜純化細胞結合劑細胞毒性劑綴合物
BR112015008376A2 (pt) *	2012-10-24	2017-09-26	Polytherics Ltd	conjugados fármaco-proteína
NO2789793T3 (fr) *	2012-10-24	2018-01-27
HUE036433T2 (hu) *	2012-11-05	2018-07-30	Pfizer	Spliceostatin analógok
CN107880126B (zh) *	2012-12-21	2021-03-30	西雅图基因公司	抗ntb-a抗体及相关组合物和方法
SI2956173T1 (sl)	2013-02-14	2017-06-30	Bristol-Myers Squibb Company	Spojine tubulizina, postopki pridobivanja in uporaba
KR102178606B1 (ko)	2013-03-15	2020-11-13	자임워크스 인코포레이티드	세포독성 및 유사분열-억제 화합물, 및 이를 사용하는 방법
JP6574754B2 (ja)	2013-03-19	2019-09-11	ベイジンシェノゲンファーマグループリミテッド	エストロゲン受容体関連疾患を処置するための抗体及び方法
US10195289B2 (en)	2013-07-31	2019-02-05	Rinat Neuroscience Corp.	Engineered polypeptide conjugates using transglutaminase
MX384608B (es)	2013-12-27	2025-03-14	Zymeworks Bc Inc	Sistemas de enlace que contienen sulfonamida para conjugados de fármacos.
AU2015205588B2 (en)	2014-01-10	2019-08-08	Byondis B.V.	Duocarmycin ADCs for use in treatment of endometrial cancer
LT3069735T (lt)	2014-01-10	2018-06-11	Synthon Biopharmaceuticals B.V.	Duokarmicino antikūno-vaisto konjugatai, skirti šlapimo pūslės vėžio gydymui
EP3092255A4 (fr) *	2014-01-10	2017-09-20	Birdie Biopharmaceuticals Inc.	Composés et compositions pour le traitement de tumeurs exprimant egfr
DK3092010T3 (en)	2014-01-10	2018-08-27	Synthon Biopharmaceuticals Bv	Process for purification of Cys-linked antibody-drug conjugates
SI3099692T1 (sl)	2014-01-27	2019-06-28	Pfizer Inc.	Bifunkcionalna citotoksična zdravila
EP3647322B1 (fr)	2014-03-20	2021-10-20	Bristol-Myers Squibb Company	Molécules de charpente à base de fibronectine stabilisée
US10314921B2 (en)	2014-04-25	2019-06-11	Pierre Fabre Medicament	Antibody-drug-conjugate and its use for the treatment of cancer
EP3134127B1 (fr)	2014-04-25	2020-02-26	Rinat Neuroscience Corp.	Conjugués anticorps-médicament à charge de médicament élevée
ES2727103T3 (es)	2014-04-25	2019-10-14	Pf Medicament	Conjugado anticuerpo-fármaco para IGF-1R y su utilización para el tratamiento del cáncer
HUE056023T2 (hu)	2014-05-22	2022-01-28	Byondis Bv	Kapcsolt drogok helyspecifikus konjugációja ellenanyagokhoz, és a kapott ADC-k
RS59643B1 (sr)	2014-06-06	2020-01-31	Bristol Myers Squibb Co	Antitela na glukokortikoidom indukovani receptor faktora nekroze tumora (gitr) i njihova primena
AU2015284236B2 (en)	2014-06-30	2018-03-08	Tva (Abc), Llc	Targeted conjugates and particles and formulations thereof
JP6473226B2 (ja)	2014-09-11	2019-02-20	シアトルジェネティックス，インコーポレイテッド	第３級アミン含有薬物物質の標的送達
RS62860B1 (sr)	2014-09-17	2022-02-28	Zymeworks Inc	Citotoksična i antimitotička jedinjenja, i postupci upotrebe istih
US10077287B2 (en)	2014-11-10	2018-09-18	Bristol-Myers Squibb Company	Tubulysin analogs and methods of making and use
SMT202000579T1 (it)	2014-11-21	2020-11-10	Bristol Myers Squibb Co	Anticorpi comprendenti regioni costanti pesanti modificate
SG10201913004UA (en)	2014-11-21	2020-03-30	Bristol Myers Squibb Co	Antibodies against cd73 and uses thereof
JP6622814B2 (ja)	2014-11-25	2019-12-18	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	イメージングのための新規ｐｄ−ｌ１結合ポリペプチド
EP4218832A3 (fr)	2014-11-25	2023-08-23	Bristol-Myers Squibb Company	Méthodes et compositions pour radiomarquage au 18f du domaine de fibronectine iii
WO2016090050A1 (fr) *	2014-12-03	2016-06-09	Genentech, Inc.	Composés d'amine quaternaire et conjugués anticorps-médicament de ceux-ci
ES2764111T3 (es)	2014-12-03	2020-06-02	Hoffmann La Roche	Anticuerpos multiespecíficos
PL3233912T3 (pl)	2014-12-19	2021-12-27	Regenesance B.V.	Przeciwciała, które wiążą ludzkie c6 oraz ich zastosowania
MX2017009144A (es)	2015-01-14	2017-11-22	Bristol Myers Squibb Co	Dimeros de benzodiazepina unidos con puentes de heteroarileno, conjugados de estos, y sus metodos de preparacion y uso.
TWI712605B (zh)	2015-03-20	2020-12-11	美商輝瑞股份有限公司	含有ｃｔｉ藥效基團之雙功能性細胞毒性劑
JP7573262B2 (ja) *	2015-07-12	2024-10-25	ハンジョウディーエーシーバイオテックシーオー．，エルティディ．	細胞結合分子の共役のための架橋連結体
MX381031B (es) *	2015-08-11	2025-03-12	Coherent Biopharma \| Ltd	Conjugados fármaco-multiligando y usos de los mismos.
EP3733698A1 (fr)	2015-09-23	2020-11-04	Bristol-Myers Squibb Company	Molécules à échafaudage à base de fibronectine se liant à la glypicane-3
KR101704379B1 (ko) *	2015-10-27	2017-02-08	(주)알테오젠	항체-약물 접합체 및 그 제조방법
CA3001712A1 (fr)	2015-10-28	2017-05-04	Tarveda Therapeutics, Inc.	Conjugues cibles sstr, et ses particules et formulations
SG11201803817PA (en)	2015-11-19	2018-06-28	Bristol Myers Squibb Co	Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
TWI727380B (zh)	2015-11-30	2021-05-11	美商輝瑞股份有限公司	位點專一性ｈｅｒ２抗體藥物共軛體
US11793880B2 (en)	2015-12-04	2023-10-24	Seagen Inc.	Conjugates of quaternized tubulysin compounds
AU2016363013B2 (en)	2015-12-04	2022-03-10	Seagen Inc.	Conjugates of quaternized tubulysin compounds
AU2017228470A1 (en)	2016-03-04	2018-08-30	Bristol-Myers Squibb Company	Combination therapy with anti-CD73 antibodies
US10994033B2 (en)	2016-06-01	2021-05-04	Bristol-Myers Squibb Company	Imaging methods using 18F-radiolabeled biologics
KR102397783B1 (ko)	2016-06-01	2022-05-12	브리스톨-마이어스 스큅 컴퍼니	Pd-l1 결합 폴리펩티드에 의한 pet 영상화
PE20190418A1 (es)	2016-07-14	2019-03-19	Bristol Myers Squibb Co	Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos
MA45945A (fr)	2016-08-09	2019-06-19	Seattle Genetics Inc	Conjugués de médicaments avec des lieurs auto-stabilisants, aux propriétés physiochimiques améliorées
EP3500574B1 (fr)	2016-08-19	2021-11-24	Bristol-Myers Squibb Company	Composés de seco-cyclopropapyrroloindole, conjugués anticorps-médicament de ceux-ci, et procédés de fabrication et d'utilisation
BR112019006778A2 (pt)	2016-10-18	2019-10-15	Seattle Genetics Inc	Composição de conjugado de aglutinante-fármaco, formulação, uso da mesma, método para preparar uma composição ou composto de conjugado de aglutinantefármaco,e, composto de ligante de fármaco
US10398783B2 (en)	2016-10-20	2019-09-03	Bristol-Myers Squibb Company	Antiproliferative compounds and conjugates made therefrom
CA3051839A1 (fr)	2017-02-17	2018-08-23	Bristol-Myers Squibb Company	Anticorps anti-alpha-synucleine et leurs utilisations
EP3607319A1 (fr)	2017-04-07	2020-02-12	Juno Therapeutics, Inc.	Cellules génétiquement modifiées exprimant un antigène membranaire spécifique de la prostate (psma) ou une forme modifiée de celui-ci et procédés associés
JP7425606B2 (ja)	2017-04-27	2024-01-31	シージェンインコーポレイテッド	四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート
CN110621337B (zh)	2017-05-10	2021-11-09	浙江时迈药业有限公司	抗lag3人单克隆抗体及其用途
CN111065623B9 (zh)	2017-05-24	2024-10-25	德克萨斯州大学系统董事会	用于抗体药物缀合物的接头
KR20240149979A (ko)	2017-05-25	2024-10-15	브리스톨-마이어스 스큅 컴퍼니	변형된 중쇄 불변 영역을 포함하는 항체
US10472361B2 (en)	2017-08-16	2019-11-12	Bristol-Myers Squibb Company	Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en)	2017-08-16	2019-11-26	Bristol-Myers Squibb Company	Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en)	2017-08-16	2019-12-03	Bristol-Myers Squibb Company	Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en)	2017-08-16	2019-12-17	Bristol-Myers Squibb Company	Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10457681B2 (en)	2017-08-16	2019-10-29	Bristol_Myers Squibb Company	Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US11364303B2 (en)	2017-09-29	2022-06-21	Pfizer Inc.	Cysteine engineered antibody drug conjugates
EP3694552A1 (fr)	2017-10-10	2020-08-19	Tilos Therapeutics, Inc.	Anticorps anti-lap et leurs utilisations
WO2019140229A1 (fr)	2018-01-12	2019-07-18	Bristol-Myers Squibb Company	Anticorps dirigés contre tim3 et leurs utilisations
KR102761890B1 (ko)	2018-03-23	2025-02-06	브리스톨-마이어스 스큅 컴퍼니	Mica 및/또는 micb에 대한 항체 및 그의 용도
MA52190A (fr)	2018-04-02	2021-02-17	Bristol Myers Squibb Co	Anticorps anti-trem-1 et utilisations associées
US11485741B2 (en)	2018-04-24	2022-11-01	Bristol-Myers Squibb Company	Macrocyclic toll-like receptor 7 (TLR7) agonists
US11884729B2 (en)	2018-06-29	2024-01-30	ApitBio, Inc	Anti-L1CAM antibodies and uses thereof
US11857638B2 (en)	2018-07-27	2024-01-02	Promega Corporation	Quinone-containing conjugates
US11554120B2 (en)	2018-08-03	2023-01-17	Bristol-Myers Squibb Company	1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
US11130802B2 (en)	2018-10-10	2021-09-28	Tilos Therapeutics, Inc.	Anti-lap antibody variants
CN113348177A (zh)	2018-11-28	2021-09-03	百时美施贵宝公司	包含经修饰的重链恒定区的抗体
US12139551B2 (en)	2018-12-03	2024-11-12	Bristol-Myers Squibb Company	Anti-IDO antibody and uses thereof
CN109762067B (zh)	2019-01-17	2020-02-28	北京天广实生物技术股份有限公司	结合人Claudin 18.2的抗体及其用途
PE20212305A1 (es)	2019-01-22	2021-12-10	Bristol Myers Squibb Co	Anticuerpos contra subunidad alfa il-7r y usos de estos
EP3999541A1 (fr)	2019-07-15	2022-05-25	Bristol-Myers Squibb Company	Anticorps dirigés contre trem-1 humain et ses utilisations
US20220372139A1 (en)	2019-07-15	2022-11-24	Bristol-Myers Squibb Company	Anti-trem-1 antibodies and uses thereof
KR102809618B1 (ko)	2019-09-04	2025-05-16	바이오션, 인코포레이티드	Tslp에 결합하는 항체 및 이의 용도
WO2021136308A1 (fr)	2020-01-03	2021-07-08	Biosion Inc.	Anticorps se liant à bcma et leurs utilisations
US20230057939A1 (en)	2020-01-13	2023-02-23	Neoimmunetech, Inc.	Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
JP7726628B2 (ja) *	2020-01-30	2025-08-20	エイムドバイオ株式会社	ベンゾセレノフェン系化合物、これを含む薬学的組成物及び抗体－薬物複合体
AU2021228061A1 (en)	2020-02-27	2022-10-13	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Antibodies binding IL4R and uses thereof
WO2021207449A1 (fr)	2020-04-09	2021-10-14	Merck Sharp & Dohme Corp.	Anticorps anti-lap à maturation d'affinité et leurs utilisations
BR112023000269A2 (pt)	2020-07-08	2023-03-28	Lava Therapeutics N V	Anticorpos que se ligam aos receptores de célula t gama-delta e psma
CN112608364B (zh) *	2020-12-09	2023-08-29	四川瀛瑞医药科技有限公司	一种果胶-阿霉素轭合物及其中间体的制备方法
CN114685669A (zh)	2020-12-30	2022-07-01	和铂医药(苏州)有限公司	结合trop2的抗体及其用途
JP2024514530A (ja)	2021-04-02	2024-04-02	ザリージェンツオブザユニバーシティオブカリフォルニア	切断型ｃｄｃｐ１に対する抗体およびその使用
JP2024539749A (ja)	2021-10-14	2024-10-29	ラッティコン（スージョウ）バイオファーマシューティカルズカンパニーリミテッド	新規な抗体－サイトカイン融合タンパク質及びその製造方法と使用
CN118900847A (zh)	2022-03-18	2024-11-05	北京天广实生物技术股份有限公司	结合b7-h3的抗体及其用途
TW202434311A (zh)	2023-02-09	2024-09-01	英屬開曼群島商百濟神州有限公司	自穩定連接子軛合物
TW202438114A (zh)	2023-03-23	2024-10-01	瑞士商百濟神州瑞士有限責任公司	生物活性結合物、其製備方法及其用途
CN118165066B (zh) *	2024-02-26	2025-03-21	复旦大学	一种含氟多肽及其制备方法和应用
WO2025184208A1 (fr)	2024-02-27	2025-09-04	Bristol-Myers Squibb Company	Anticorps anti-ceacam5 et leurs utilisations
US20250282786A1 (en)	2024-03-05	2025-09-11	Bristol-Myers Squibb Company	Tricyclic TLR7 Agonists and Uses Thereof
WO2025188693A1 (fr)	2024-03-05	2025-09-12	Bristol-Myers Squibb Company	Agonistes de tlr7 bicycliques et leurs utilisations

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4169888A (en) *	1977-10-17	1979-10-02	The Upjohn Company	Composition of matter and process
US4391904A (en)	1979-12-26	1983-07-05	Syva Company	Test strip kits in immunoassays and compositions therein
US4671958A (en) *	1982-03-09	1987-06-09	Cytogen Corporation	Antibody conjugates for the delivery of compounds to target sites
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4912227A (en) *	1984-02-21	1990-03-27	The Upjohn Company	1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds
US4978757A (en)	1984-02-21	1990-12-18	The Upjohn Company	1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds
US5225539A (en) *	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
EP0271581B1 (fr) *	1986-04-17	1993-01-13	Kyowa Hakko Kogyo Co., Ltd.	Nouveaux composes dc-88a et dc-89a1, et procede pour leur preparation
US5332837A (en)	1986-12-19	1994-07-26	The Upjohn Company	CC-1065 analogs
US4975278A (en) *	1988-02-26	1990-12-04	Bristol-Myers Company	Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4952394A (en) *	1987-11-23	1990-08-28	Bristol-Myers Company	Drug-monoclonal antibody conjugates
US4994578A (en) *	1987-11-27	1991-02-19	Meiji Seika Kaisha, Ltd.	Certain anti-tumor duocarmycin antibiotics from streptomyces
US5147786A (en) *	1988-04-22	1992-09-15	Monsanto Company	Immunoassay for the detection of α-haloacetamides
JP2642165B2 (ja) *	1988-07-22	1997-08-20	協和醗酵工業株式会社	新規ｄｃ−８９化合物およびその製造法
US5084468A (en) *	1988-08-11	1992-01-28	Kyowa Hakko Kogyo Co., Ltd.	Dc-88a derivatives
US5223409A (en) *	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5194599A (en)	1988-09-23	1993-03-16	Gilead Sciences, Inc.	Hydrogen phosphonodithioate compositions
DE3837648A1 (de)	1988-11-05	1990-05-10	Basf Ag	Vorrichtung zur auswaschung von photopolymeren druckplatten mittels loesungsmitteln, trocknung der druckplatten und rueckgewinnung der loesungsmittel
US5176996A (en) *	1988-12-20	1993-01-05	Baylor College Of Medicine	Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
JP2598116B2 (ja)	1988-12-28	1997-04-09	協和醗酵工業株式会社	新規物質ｄｃ１１３
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
DE3907562A1 (de)	1989-03-09	1990-09-13	Bayer Ag	Antisense-oligonukleotide zur inhibierung der transaktivatorzielsequenz (tar) und der synthese des transaktivatorproteins (tat) aus hiv-1 und deren verwendung
EP0471796A4 (en)	1989-05-10	1993-05-05	Sloan Kettering Institute For Cancer Research	Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter
CA2058632C (fr)	1989-06-05	2004-08-24	Brian C. Froehler	Oligonucleotides resistant a l'exonuclease et methodes de preparation
US5187186A (en)	1989-07-03	1993-02-16	Kyowa Hakko Kogyo Co., Ltd.	Pyrroloindole derivatives
JP2510335B2 (ja)	1989-07-03	1996-06-26	協和醗酵工業株式会社	Ｄｃ―８８ａ誘導体
WO1991004753A1 (fr)	1989-10-02	1991-04-18	Cetus Corporation	Conjugues d'oligonucleotides non codants et leurs emplois therapeutiques
US5399676A (en)	1989-10-23	1995-03-21	Gilead Sciences	Oligonucleotides with inverted polarity
US5495009A (en) *	1989-10-24	1996-02-27	Gilead Sciences, Inc.	Oligonucleotide analogs containing thioformacetal linkages
JPH05504552A (ja)	1989-10-24	1993-07-15	ギリアド　サイエンシズ，インコーポレイテッド	２’位が改変されたオリゴヌクレオチド
DE69027443T2 (de)	1989-10-24	1998-03-19	Gilead Sciences, Inc., Foster City, Calif.	Oligonukleotidanaloga mit neuartigen bindungen
US5334528A (en) *	1989-10-30	1994-08-02	The Regents Of The University Of California	Monoclonal antibodies to cyclodiene insecticides and method for detecting the same
US5180819A (en)	1989-12-22	1993-01-19	The Trustees Of Columbia University In The City Of New York	Purified myeloblastin, nucleic acid molecule encoding same, and uses thereof
US6075181A (en) *	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
ATE139258T1 (de) *	1990-01-12	1996-06-15	Cell Genesys Inc	Erzeugung xenogener antikörper
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
WO1991011535A1 (fr)	1990-01-30	1991-08-08	Childrens Hospital Of Los Angeles	Inhibition de transcription a l'aide d'oligonucleotides bicatenaires
WO1991013080A1 (fr)	1990-02-20	1991-09-05	Gilead Sciences, Inc.	Pseudonucleosides, pseudonucleotides et leurs polymeres
EP0527189A1 (fr)	1990-04-25	1993-02-17	PHARMACIA & UPJOHN COMPANY	Nouveaux analogues de cc-1065
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
US5137877B1 (en) *	1990-05-14	1996-01-30	Bristol Myers Squibb Co	Bifunctional linking compounds conjugates and methods for their production
ATE160821T1 (de)	1990-06-11	1997-12-15	Nexstar Pharmaceuticals Inc	Nukleinsäureliganden
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
EP0468400B1 (fr) *	1990-07-26	1996-08-14	Kyowa Hakko Kogyo Co., Ltd.	Dérivés de DC-89 comme agents antitumoraux
GB9017024D0 (en) *	1990-08-03	1990-09-19	Erba Carlo Spa	New linker for bioactive agents
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de)	1990-08-29	1998-02-19	Genpharm Int	Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
WO1992005186A1 (fr)	1990-09-20	1992-04-02	Gilead Sciences	Liaisons internucleosides modifiees
JPH06503715A (ja)	1990-09-21	1994-04-28	フレッドハッチンソンキャンサーリサーチセンター	タンパク質配列特異的オリゴヌクレオチド配列
AU9094991A (en)	1990-11-23	1992-06-25	Gilead Sciences, Inc.	Triplex-forming oligomers containing modified bases
WO1992010590A1 (fr)	1990-12-10	1992-06-25	Gilead Sciences, Inc.	Inhibition de transcription par formation de triple helice
AU1435492A (en)	1991-02-21	1992-09-15	Gilead Sciences, Inc.	Aptamer specific for biomolecules and method of making
JPH0597853A (ja)	1991-10-07	1993-04-20	Kyowa Hakko Kogyo Co Ltd	Ｄｃ−８９誘導体の臭化水素酸塩
ES2227512T3 (es)	1991-12-02	2005-04-01	Medical Research Council	Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5622929A (en) *	1992-01-23	1997-04-22	Bristol-Myers Squibb Company	Thioether conjugates
GB9314960D0 (en) *	1992-07-23	1993-09-01	Zeneca Ltd	Chemical compounds
JP3514490B2 (ja) *	1992-08-21	2004-03-31	杏林製薬株式会社	トリフルオロメチルピロロインドールカルボン酸エステル誘導体及びその製造方法
US5288514A (en)	1992-09-14	1994-02-22	The Regents Of The University Of California	Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5324483B1 (en)	1992-10-08	1996-09-24	Warner Lambert Co	Apparatus for multiple simultaneous synthesis
DE4314091A1 (de)	1993-04-29	1994-11-03	Boehringer Mannheim Gmbh	Immunologisches Nachweisverfahren für Triazine
US6214345B1 (en) *	1993-05-14	2001-04-10	Bristol-Myers Squibb Co.	Lysosomal enzyme-cleavable antitumor drug conjugates
DE69533277T2 (de) *	1994-04-22	2005-07-21	Kyowa Hakko Kogyo Co., Ltd.	Dc-89 derivat
JPH07309761A (ja)	1994-05-20	1995-11-28	Kyowa Hakko Kogyo Co Ltd	デュオカルマイシン誘導体の安定化法
AU694546C (en) *	1994-08-19	2001-09-06	La Region Wallonne	Compounds, pharmaceutical composition and diagnostic device comprising same and their use
AU3532895A (en)	1994-09-30	1996-04-26	Kyowa Hakko Kogyo Co. Ltd.	Antitumor agent
US6103236A (en) *	1995-05-10	2000-08-15	Kyowa Hakko Kogyo Co., Ltd.	Toxin conjugates
US5686237A (en)	1995-06-05	1997-11-11	Al-Bayati; Mohammed A. S.	Use of biomarkers in saliva to evaluate the toxicity of agents and the function of tissues in both biomedical and environmental applications
CA2233936A1 (fr) *	1995-10-03	1997-04-10	The Scripps Research Institute	Analogues de cbi de cc-1065 et des duocarmycines
ATE272058T1 (de) *	1995-10-17	2004-08-15	Combichem Inc	Matrize für die synthese kombinatorischer bibliotheken in lösung
WO1997023243A1 (fr) *	1995-12-22	1997-07-03	Bristol-Myers Squibb Company	Segments de liaison hydrazone ramifies
US6143901A (en) *	1996-07-31	2000-11-07	Genesoft, Inc.	Complex formation between dsDNA and pyrrole imidazole polyamides
US6130237A (en) *	1996-09-12	2000-10-10	Cancer Research Campaign Technology Limited	Condensed N-aclyindoles as antitumor agents
JPH1087666A (ja) *	1996-09-18	1998-04-07	Kyorin Pharmaceut Co Ltd	デュオカルマイシンｓａ及びその誘導体の製造中間体と製造方法
US6759509B1 (en) *	1996-11-05	2004-07-06	Bristol-Myers Squibb Company	Branched peptide linkers
CA2289115A1 (fr) *	1997-05-07	1998-11-12	Bristol-Myers Squibb Company	Proteines fusionnees d'enzymes anticorps produites par recombinaison
DE69825048D1 (de) *	1997-05-22	2004-08-19	Scripps Research Inst	Analoga von duocarmycin and cc-1065
CA2306420A1 (fr) *	1997-10-14	1999-04-22	The Scripps Research Institute	Analogues iso-cbi ou iso-ci du cc-1065 et duocarmycines
NZ504884A (en) *	1997-12-08	2002-10-25	Scripps Research Inst	Synthesis of the dihydroindole C-ring of CC-1065/duocarmycin analogs and certain intermediates
JP3045706B1 (ja) *	1998-09-14	2000-05-29	科学技術振興事業団	Ｄｎａの特定塩基配列をアルキル化する化合物及びその合成法
US7425541B2 (en) *	1998-12-11	2008-09-16	Medarex, Inc.	Enzyme-cleavable prodrug compounds
DE60031793T2 (de) *	1999-12-29	2007-08-23	Immunogen Inc., Cambridge	Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
EP1265921B1 (fr) *	2000-03-16	2007-05-23	Genesoft, Inc.	Composes charges comprenant une fraction de liaison de l'acide nucleique et leurs utilisations
JP4061819B2 (ja) *	2000-05-12	2008-03-19	独立行政法人科学技術振興機構	インターストランドクロスリンク剤の合成方法
CA2411545A1 (fr) *	2000-06-14	2002-01-03	Medarex, Inc.	Composes de tripeptide pour promedicaments
EP1294404A2 (fr) *	2000-06-14	2003-03-26	Corixa Corporation	Composes de promedicaments contenant de l'isoleucine
AU2002239422B2 (en)	2000-11-30	2006-12-07	E. R. Squibb & Sons, L.L.C.	Transgenic transchromosomal rodents for making human antibodies
EP1243276A1 (fr)	2001-03-23	2002-09-25	Franciscus Marinus Hendrikus De Groot	Prodrogues activables à séparateurs allongés et multiples
US20030083263A1 (en) *	2001-04-30	2003-05-01	Svetlana Doronina	Pentapeptide compounds and uses related thereto
US7256257B2 (en) *	2001-04-30	2007-08-14	Seattle Genetics, Inc.	Pentapeptide compounds and uses related thereto
US6884869B2 (en) *	2001-04-30	2005-04-26	Seattle Genetics, Inc.	Pentapeptide compounds and uses related thereto
CN101671335A (zh)	2001-05-31	2010-03-17	梅达莱克斯公司	细胞毒素、其有用的前体药物、连接基团和稳定剂
MXPA03010961A (es) *	2001-05-31	2004-02-27	Vertex Pharma	Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
MXPA03010804A (es) *	2001-06-01	2004-11-22	Cornell Res Foundation Inc	Anticuerpos modificados para antigeno de membrana especifico de la prostata y usos de los mismos.
US7514078B2 (en) *	2001-06-01	2009-04-07	Cornell Research Foundation, Inc.	Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
AU2002316539C1 (en) *	2001-06-11	2008-10-30	Medarex, Inc.	CD10-activated prodrug compounds
CA2459308A1 (fr) *	2001-09-07	2003-03-20	Dale L. Boger	Analogues cbi de cc-1065 et des duocarmycines
US7091186B2 (en)	2001-09-24	2006-08-15	Seattle Genetics, Inc.	p-Amidobenzylethers in drug delivery agents
WO2003026577A2 (fr)	2001-09-24	2003-04-03	Seattle Genetics, Inc.	P-aminobenzyl ether dans des agents d'administration de medicaments
US6756397B2 (en) *	2002-04-05	2004-06-29	Immunogen, Inc.	Prodrugs of CC-1065 analogs
US6534660B1 (en) *	2002-04-05	2003-03-18	Immunogen, Inc.	CC-1065 analog synthesis
WO2004005327A1 (fr)	2002-07-09	2004-01-15	Morphochem Ag Komb Chemie	Nouveaux analogues de tubulysine
AU2003253048A1 (en)	2002-07-09	2004-01-23	Morphochem Aktiengellschaft Fur Kombinatorische Chemie	Tubulysin conjugates
CA2494104A1 (fr) *	2002-07-31	2004-04-22	Seattle Genetics, Inc.	Conjugues anticorps anti-cd20-medicament pour le traitement du cancer et des troubles immunitaires
AU2003282624A1 (en)	2002-11-14	2004-06-03	Syntarga B.V.	Prodrugs built as multiple self-elimination-release spacers
AU2004213053C1 (en) *	2003-02-20	2009-07-16	Seagen Inc.	Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
WO2004101767A2 (fr) *	2003-05-13	2004-11-25	The Scripps Research Institute	Analogues cbi des duocarmycines et de cc-1065
PL1725249T3 (pl) *	2003-11-06	2014-06-30	Seattle Genetics Inc	Związki monometylowaliny zdolne do sprzęgania do ligandów
WO2005094882A1 (fr) *	2004-03-03	2005-10-13	Millennium Pharmaceuticals, Inc.	Anticorps modifies diriges contre un antigene membranaire specifique de la prostate
AU2005244980B2 (en) *	2004-05-19	2011-09-15	E. R. Squibb & Sons, L.L.C.	Chemical linkers and conjugates thereof
WO2006089231A2 (fr) *	2005-02-18	2006-08-24	Medarex, Inc.	Anticorps monoclonaux diriges contre l'antigene d'enveloppe specifique de la prostate (psma) depourvus de residus fucosyle

2006
- 2006-09-26 ES ES06825196T patent/ES2416136T3/es active Active
- 2006-09-26 EP EP11155501.7A patent/EP2354163A3/fr not_active Withdrawn
- 2006-09-26 CA CA2623652A patent/CA2623652C/fr not_active Expired - Fee Related
- 2006-09-26 CN CNA2006800440128A patent/CN101312748A/zh active Pending
- 2006-09-26 WO PCT/US2006/037793 patent/WO2007038658A2/fr not_active Ceased
- 2006-09-26 NZ NZ566982A patent/NZ566982A/en not_active IP Right Cessation
- 2006-09-26 AU AU2006294554A patent/AU2006294554B2/en not_active Ceased
- 2006-09-26 US US12/088,066 patent/US20080279868A1/en not_active Abandoned
- 2006-09-26 BR BRPI0617546-5A patent/BRPI0617546A2/pt not_active IP Right Cessation
- 2006-09-26 EP EP06825196.6A patent/EP1940470B1/fr active Active
- 2006-09-26 JP JP2008532509A patent/JP5290756B2/ja not_active Expired - Fee Related
- 2006-09-26 EA EA200800952A patent/EA016577B1/ru not_active IP Right Cessation
2008
- 2008-03-16 IL IL190187A patent/IL190187A/en not_active IP Right Cessation
- 2008-04-10 ZA ZA200803153A patent/ZA200803153B/xx unknown
- 2008-04-22 KR KR1020087009646A patent/KR101377373B1/ko not_active Expired - Fee Related
- 2008-04-24 NO NO20081974A patent/NO20081974L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP2009509977A (ja)	2009-03-12
JP5290756B2 (ja)	2013-09-18
WO2007038658A2 (fr)	2007-04-05
CA2623652A1 (fr)	2007-04-05
AU2006294554B2 (en)	2013-03-21
KR20080057310A (ko)	2008-06-24
BRPI0617546A2 (pt)	2011-07-26
US20080279868A1 (en)	2008-11-13
NZ566982A (en)	2011-06-30
ZA200803153B (en)	2009-02-25
AU2006294554A1 (en)	2007-04-05
EP2354163A2 (fr)	2011-08-10
ES2416136T3 (es)	2013-07-30
WO2007038658A3 (fr)	2007-10-18
CA2623652C (fr)	2013-11-26
EP1940470A2 (fr)	2008-07-09
IL190187A (en)	2015-05-31
EA200800952A1 (ru)	2009-02-27
EP2354163A3 (fr)	2013-04-24
EP1940470B1 (fr)	2013-04-17
IL190187A0 (en)	2008-11-03
EA016577B1 (ru)	2012-06-29
CN101312748A (zh)	2008-11-26
HK1117410A1 (en)	2009-01-16
KR101377373B1 (ko)	2014-03-21

Publication	Publication Date	Title
NO20081974L (no)	2008-06-09	Antistoff-drug-konjugater og fremgangsmater for anvendelse av disse
NO20065881L (no)	2007-02-13	Kjemiske bindinger og konjugater derav
EA200601670A1 (ru)	2007-02-27	Конъюгаты гидроксиалкилкрахмала и белка
NO20083895L (no)	2008-10-24	Anti-IGF-1R human monoklonalantibody formulering
TW200833683A (en)	2008-08-16	Chemical linkers and cleavable substrates and conjugates thereof
UA92505C2 (ru)	2010-11-10	Композиции на основе антитела против cd3
MX2021015221A (es)	2022-03-17	Compuestos de aminobenzazepina, inmunoconjugados y usos de estos.
NO20083698L (no)	2008-11-12	Prosesser for den konvergerende syntesen av Calicheamicin derivater
MA30531B1 (fr)	2009-06-01	Anticorps anti-dll4 et leurs procedes d'utilisation
NO20073788L (no)	2007-09-03	Kjemiske forbindelser
EA200702053A1 (ru)	2008-02-28	Антитела против cd38 для лечения множественной миеломы
ATE522518T1 (de)	2011-09-15	Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
NO20084752L (no)	2008-12-17	Konjugater av aziridinayl-epotilonanaloger og farmasoytiske sammensetninger som inneholder disse
NO20083891L (no)	2008-12-03	Anti-5T4 antistoffer og anvendelser derav
EA201070163A1 (ru)	2010-08-30	Цитотоксические средства, включающие новые производные томаймицина, и их терапевтическое применение
GB0619291D0 (en)	2006-11-08	Altered antibodies
TW200642694A (en)	2006-12-16	Anti-M-CSF antibody compositions
EA200870193A1 (ru)	2009-02-27	Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
NO20084480L (no)	2008-12-19	Diaryltiohydantoin forbindelser
MX2010006206A (es)	2011-03-04	Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
NO20061845L (no)	2006-06-26	Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
NO20075140L (no)	2007-12-07	Fremgangsmater og preparater for modulering av vaskulaer integritet
EA200801414A1 (ru)	2008-10-30	Кальцилитические соединения
EA200700550A1 (ru)	2007-10-26	Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
EA200701688A1 (ru)	2007-12-28	Замещённые пирролы, содержащие их композиции, способ получения и применение

Legal Events

Date	Code	Title	Description
2013-06-10	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: MEDAREX, US
2017-12-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application